This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Pain	Adrenergic receptor α_{2c} (ADRA2C); ADRA2A	<i>In vitro</i> and mouse studies suggest imidazoline analogs that target ADRA2C and ADRA2A could be used to reduce side effects associated with the pain drug morphine. In mouse models of pain, the analogs in combination with morphine induced longer-lasting analgesia with less sedation than morphine plus a placebo. Ongoing work includes analyzing the isomeric forms of the analogs. Addrenex Pharmaceuticals Inc.'s Clonicef clonidine, a modified release formulation of the ADRA2 agonist clonidine, is in registration to treat attention deficit hyperactivity disorder (ADHD).	Unpatented; unlicensed	Cardinaletti, C. <i>et al. J. Med. Chem.</i> ; published online Nov. 3, 2009; doi:10.1021/jm901262f Contact: Maria Pigni, University of Camerino, Camerino, Italy e-mail: maria.pigni@unicam.it
<i>SciBX</i> 2(44); doi:10.1038/scibx.2009.1639 Published online Nov. 12, 2009				